IP Verse

Process For Preparation Of Apremilast - EP3341359

The patent EP3341359 was granted to Glenmark Life Sciences on Jan 22, 2025. The application was originally filed on Aug 22, 2016 under application number EP16838641A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3341359

GLENMARK LIFE SCIENCES
Application Number
EP16838641A
Filing Date
Aug 22, 2016
Status
Patent Maintained As Amended
Dec 20, 2024
Grant Date
Jan 22, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPDec 22, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN104478790
DESCRIPTIONUS2014081032
DESCRIPTIONWO03080049
DESCRIPTIONWO2016066116
DESCRIPTIONWO2016192694
DESCRIPTIONWO2016199031
DESCRIPTIONWO2017085568
EXAMINATIONWO03080049
EXAMINATIONWO2016066116
EXAMINATIONWO2016199031
INTERNATIONAL-SEARCH-REPORTCN104447443
INTERNATIONAL-SEARCH-REPORTCN105330586
INTERNATIONAL-SEARCH-REPORTWO03080049
INTERNATIONAL-SEARCH-REPORTWO2016066116
OPPOSITIONCN104478790
OPPOSITIONWO03080049
SEARCHCN104478790
SEARCHUS2014081032
SEARCHWO2016192694
SEARCHWO2017085568

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Nucleophilic substitution at the carbonyl (C=O) group", Anonymous, Clayden J.; Greeves N.; Warren S.; Wothers P., Organic Chemistry, US , Oxford university Press , (20010101), pages 286 - 293, ISBN 978-0-19-850346-0, XP093166748-
OPPOSITION- BOWEN J, BREUER P, LANO K, "A COMPENDIUM OF FORMAL TECHNIQUES FOR SOFTWARE MAINTENANCE", SOFTWARE ENGINEERING JOURNAL., IEE. LONDON., GB, GB , (19930901), vol. 26, no. 10-11, ISSN 0268-6961, pages 253 - 262, XP002923524-
OPPOSITION- Ema, "Otezla", Assessment Report V/H/C/003746, (20141120), pages 1 - 189, Assessment Report V/H/C/003746, (20230112), XP093013261-
OPPOSITION- Heinz G. O. Becker, "2.2 Kristallisieren", Organikum, Berlin , Deutscher Verlag der Wissenschaften , (19880101), pages 32 - 34, ISBN 3-326-00076-6, XP009555190-
OPPOSITION- Hon-Wah Man, Peter Schafer, Lu Min Wong, Rebecca T. Patterson, Laura G. Corral, Heather Raymon, Kate Blease, Jim Leisten, Michael A. Shirley, Yang Tang, Darius M. Babusis, Roger Chen, Dave Stirling, George W. Muller, "Discovery of ( S )- N -{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1 H -isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20090326), vol. 52, no. 6, doi:10.1021/jm900210d, ISSN 0022-2623, pages 1522 - 1524-
OPPOSITION- March J., "Hydrolysis of amides", Advanced Organic Chemistry, John Wiley & Sons, (19920101), pages 383 - 386, 418-419, XP093013096-
OPPOSITION- Stahl P H, Wermuth C G, "chapter 12: Monographs on acids and bases", Stahl P H, Wermuth C G, P. Heinrich Stahl; Camille G. Wermuth (eds.), Handbook of pharmaceutical salts : properties, selection, and use, Weinheim , WILEY-VCH , (20020101), pages 265 - 327, ISBN 978-3-906390-26-0, XP008145189-
OPPOSITION- Hon-Wah Man, Peter Schafer, Lu Min Wong, Rebecca T. Patterson, Laura G. Corral, Heather Raymon, Kate Blease, Jim Leisten, Michael A. Shirley, Yang Tang, Darius M. Babusis, Roger Chen, Dave Stirling, George W. Muller, "Discovery of ( S )- N -{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1 H -isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20090326), vol. 52, no. 6, doi:10.1021/jm900210d, ISSN 0022-2623, pages 1522 - 1524, XP055243604

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents